Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.

Détails

Ressource 1Télécharger: BIB_267B22276362.P001.pdf (173.59 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_267B22276362
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Mycophenolic acid formulations in adult renal transplantation - update on efficacy and tolerability.
Périodique
Therapeutics and Clinical Risk Management
Auteur(s)
Golshayan D., Pascual M., Vogt B.
ISSN
1176-6336
Statut éditorial
Publié
Date de publication
2009
Peer-reviewed
Oui
Volume
5
Numéro
4
Pages
341-351
Langue
anglais
Résumé
The description more than 30 years ago of the role of de novo purine synthesis in T and B lymphocytes clonal proliferation opened the possibility for selective immunosuppression by targeting specific enzymatic pathways. Mycophenolic acid (MPA) blocks the key enzyme inosine monophosphate dehydrogenase and the production of guanosine nucleotides required for DNA synthesis. Two MPA formulations are currently used in clinical transplantation as part of the maintenance immunosuppressive regimen. Mycophenolate mofetil (MMF) was the first MPA agent to be approved for the prevention of acute rejection following renal transplantation, in combination with cyclosporine and steroids. Enteric-coated mycophenolate sodium (EC-MPS) is an alternative MPA formulation available in clinical transplantation. In this review, we will discuss the clinical trials that have evaluated the efficacy and safety of MPA in adult kidney transplantation for the prevention of acute rejection and their use in new combination regimens aiming at minimizing calcineurin inhibitor toxicity and chronic allograft nephropathy. We will also discuss MPA pharmacokinetics and the rationale for therapeutic drug monitoring in optimizing the balance between efficacy and safety in individual patients.
Pubmed
Création de la notice
03/07/2009 13:24
Dernière modification de la notice
20/08/2019 13:05
Données d'usage